An offering of equity and convertible notes involving 152 unidentified investors has pulled in $14.5 million for BioVentrix, according to a filing with the SEC. The company, which makes the Revivent TC transcatheter ventricular enhancement system, is not looking to raise more funds in the round.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.